Chronic Pain News and Research

RSS

Pain services severely inadequate: report

The Patients Association has urged the Government to create a clear care pathway for chronic pain services throughout the National Health Service. This came in after a survey of more than 4,000 patients revealed significant shortcomings in care.

11 Jan 2011

General anaesthesia brings reversible coma and not sleep: Study

Anaesthesia has been one of the greatest gifts of science and use of general anaesthesia is a routine part of surgical operations at hospitals and medical facilities around the world. However precise biological mechanisms of the drugs’ effects on the brain are only now being analyzed. In a review article published this week in the New England Journal of Medicine, scientists have tried to analyze a range of disciplines, including neuroscience and sleep medicine to understand how anaesthesia actually works.

2 Jan 2011

NDA resubmitted for DURECT's ORADUR technology based REMOXY

DURECT Corporation today reported that King Pharmaceuticals, Inc. and Pain Therapeutics, Inc. have announced that King has resubmitted a New Drug Application (NDA) for REMOXY® to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter received by Pain Therapeutics in December 2008. This is a Class 2 resubmission with a six month review cycle.

28 Dec 2010

Spinal Botox injection reduces pain

Botulinum neurotoxin type A (BoNT/A)—better known as Botox—reduces responses to an inflammation-related pain stimulus when injected into the spinal canal in mice, reports a study in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

22 Dec 2010

Scientists suggest targeting ion channels could offer effective pain relief

University at Buffalo neuroscience researchers conducting basic research on ion channels have demonstrated a process that could have a profound therapeutic impact on pain.

20 Dec 2010

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Pico-Tesla, The Magneceutical® Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have fibromyalgia. The pilot study seeks to determine whether the application of magnetic fields generated by Pico-Tesla's patented Resonator™ system can be effective as an adjunctive therapy to oral medications in ameliorating the symptoms of fibromyalgia.

16 Dec 2010

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Multiple myeloma, a type of blood cancer in which malignant plasma cells are overproduced in the bone marrow, has led to an estimated 20,000 new diagnoses and 11,000 deaths in 2010. Patients with the disease, who have already failed previous treatments, may be considered for a currently enrolling Phase II study, examining a unique drug combination.

14 Dec 2010

Depression drug appears effective in reducing pain associated with breast cancer treatment

A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.

12 Dec 2010

31-year-old mother with Gorham-Stout syndrome goes home with virtually rebuilt spine

Laurie Harms, Los Angeles, feared she'd never hold her infant daughter, Sky, again. A devastating and extremely rare bone-eroding disease - Gorham-Stout syndrome - had left the 31-year-old crumpled in a hospital bed - her neck broken, arms limp and useless, and voice muted by tubes.

10 Dec 2010

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

BioDelivery Sciences International, Inc. today announced the enrollment and dosing of the first patient in its Phase 3 clinical program evaluating the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

9 Dec 2010

New study shows how meditators don't ponder pain

Zen meditation has many health benefits, including a reduced sensitivity to pain. According to new research from the Universit- de Montr-al, meditators do feel pain but they simply don't dwell on it as much. These findings, published in the month's issue of Pain, may have implications for chronic pain sufferers, such as those with arthritis, back pain or cancer.

9 Dec 2010

Third Edition of Occupational Medicine Practice Guidelines released

The American College of Occupational and Environmental Medicine (ACOEM) has released the Third Edition of Occupational Medicine Practice Guidelines to subscribers of the guideline development and content publishing platform, APG-I. The proprietary, evidence-based system provides full access to ACOEM's complete guidelines, featuring thousands of pages of the most current evidence medical treatment recommendations.

7 Dec 2010

Neurostimulation effective for management of chronic pain

St. Jude Medical, Inc., a global medical device company, today announced two-year results in a post-market clinical study evaluating neurostimulation (spinal cord stimulation) for the management of chronic low back pain. Presented at the 14th annual North American Neuromodulation Society (NANS) meeting in Las Vegas, the study found that 70 percent of neurostimulation patients reported overall pain relief of 50 percent or better at their final two-year visit.

4 Dec 2010

Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain

Zogenix, Inc. today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.

30 Nov 2010

Spinal Modulation's Dorsal Root Ganglion Stimulation Pilot Clinical Trial results to be presented at 14th NANS

SPINAL MODULATION, Inc., a privately held medical device company focused on developing devices to treat chronic pain, today announced that the results of its prospective, multicenter Dorsal Root Ganglion (DRG) Stimulation Clinical Trial will be presented by David Caraway, MD, PhD, Timothy Deer, MD and Robert Levy, MD, PhD at the 14th Annual North American Neuromodulation Society (NANS) meeting.

30 Nov 2010

Study finds chronic pain can affect every aspect of a person’s life

Coping with chronic pain can affect every aspect of a person's life and cause conflict between what their mind wants to achieve and what their body allows them to do, according to research in the December issue of the Journal of Nursing and Healthcare of Chronic Illness.

30 Nov 2010

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.

29 Nov 2010

American Board Diplomat joins Ascendant Neuro for treating pain management

Ascendant Neuro is pleased to announce the addition of Jack A. Chapman, M.D., a nationally recognized pain management specialist, who will work to further advance the group's minimally invasive pain treatment techniques through the innovative use of neurostimulators and other conservative treatments.

25 Nov 2010

Convergence enters drug discovery collaboration with Selcia for chronic pain treatment

Convergence Pharmaceuticals Limited, the new company focused on the development of novel and high value analgesic medicines, and Selcia Limited, a contract research organisation, today are pleased to announce that they have entered into a drug discovery collaboration to identify and develop high quality candidate molecules for the treatment of chronic pain.

22 Nov 2010

FDA clears Multi-Lead Trialing Cable for SCS therapy

Medtronic Inc., the leader in spinal cord stimulation for more than 25 years, today announced U.S. Food and Drug Administration (FDA) clearance and the global launch of the Multi-Lead Trialing Cable for use in the patient screening test for Medtronic spinal cord stimulation (SCS) therapy.

19 Nov 2010